CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it has appointed Bettina M. Cockroft, M.D., M.B.A., to its Board of Directors as an independent director.